The Breathalyzers Market, estimated at USD 14.91 Bn in 2025, is expected to exhibit a CAGR of 18.6% and reach USD 49.21 Bn by 2032.
The industry is witnessing significant growth driven by rising demand for advanced, reliable, and cost-effective medical devices across diagnostic, therapeutic, and monitoring applications. Rapid advancements in device design, digital health integration, and adoption of minimally invasive technologies are reshaping the competitive landscape. Furthermore, supportive regulatory frameworks, increasing healthcare investments, and the growing focus on patient-centric care are expected to create new growth avenues for market players.
Major players in the market are focused on adopting partnership strategies to enhance their market share. For instance, in December 2025, Hound Labs, Inc., is THC breath test manfracturing designed for workplace safety and employee privacy in the era of cannabis legalization, announced its partnership with Cynergy Wellness, Inc., a privately-owned provider of nationwide physician services for workplace screening and consumer health. Under the terms of the partnership, employers using the HOUND CANNABIS BREATHALYZER will have the option to access Cynergy’s Medical Review Officer (MRO) services as part of their drug testing programs.
Global Breathanalyzers Market – Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2025 as "coronavirus disease 2025" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems with regard to the transportation of drugs from one place to another.
COVID-19 had a positive impact on the global Breathanalyzers market. For instance, in April 2025, the U.S. FDA approved the first COVID-19 breathalyzer test developed by InspectIR Systems, LLC is Research, Development & Device Company Dedicated to Community Wellness and Health. The test provides results within three minutes and detects five volatile organic compounds (VOCs) associated with COVID-19. The COVID-19 pandemic notably impacted the market. The pandemic also increased the demand for non-invasive testing solutions that could be performed while adhering to social distancing norms. Breathalyzers thus emerged as viable alternatives in detecting COVID-19 and other medical diseases without the risk of transmission.
Global Breathanalyzers Market: Key Developments
In July 2025, Lifeloc Technologies Inc is manufracturing of Breathanalyzers, introduced two handheld breath alcohol testers (Breathalyzers) - LT7 and LX9. These testers are USA DOT/NHTSA-approved breath alcohol testers (Breathalyzers) for law enforcement and workplace markets with enhanced features that make them user-friendly while helping to create safer roadways and communities.
In June 2025, Abbott, a multinational medical devices and healthcare company, with headquarters in U.S. and Intoximeters is the provider of breath alcohol testers, announced an agreement for Intoximeters to market Abbott's SoToxaTM Mobile Test System. a handheld oral fluid roadside testing solution that rapidly and reliably detects drug use alongside Intoximeters Alco-Sensor brand breath alcohol-testing products. This agreement aid law enforcement agencies in their efforts to reduce the rate of drugged driving, which has become a serious road safety issue.